The global cytokine release syndrome (CRS) management market is projected to achieve a valuation of USD 23.32 billion in 2023, with an anticipated compound annual growth rate (CAGR) of 6.7% from 2023 to 2033.
The growth of the CRS management market is primarily attributed to the rising incidence of autoimmune diseases and cancers, which are increasingly recognized as significant contributors to the development of cytokine release syndrome. As more patients undergo innovative therapies, such as CAR T-cell treatments, the demand for effective management strategies to address CRS is expected to surge.
Healthcare providers and researchers are focused on developing comprehensive treatment protocols to mitigate the effects of CRS, leading to improved patient outcomes. With the growing awareness of cytokine release syndrome and advancements in therapeutic options, the market for CRS management is set to expand significantly in the coming years.
A new generation of drugs such as tocilizumab, siltuximab, and anakinra have revolutionized the treatment of Cytokine Release Syndrome (CRS). Using these drugs can reduce the severity of CRS by reducing the production of pro-inflammatory cytokines. Symptoms associated with CRS can also be reduced with aggressive supportive care, such as fluid resuscitation, anti-emesis, and anti-diarrhea medication. CRS can be treated early and prevent long-term complications by recognizing it early and treating it promptly.
A very promising future lies ahead for the management of cytokine release syndrome. Symptoms of cytokine release syndrome are increasingly being treated and managed through immunotherapy treatments. Additionally, there are numerous studies that are being conducted to better understand the underlying mechanisms that cause cytokine release syndrome, as well as the potential treatment options available for the disease. There is therefore an increasing likelihood that effective interventions will be available in the future. As a result, the outlook for the management of cytokine-release syndromes in the near future is promising.
Market Competition
Increased production and meeting consumer demands can boost manufacturers’ revenue and market share. Promote new products and technologies in order to benefit end users. Strategic partnerships allow a company to become more productive by increasing its capacity as a result of forming a partnership.
- Legend Biotech Corporation, as part of its ongoing development, manufacturing, and marketing of novel therapies for life-threatening diseases, a global biotechnology company announced its New Drug Application (NDA) for ciltacabtagene autoleucel (cilta-cel) was accepted by the National Medical Products Administration (NMPA). The data in this submission are from the CARTIFAN-1 (NCT03758417) confirmatory Phase 2 clinical trial conducted in China to determine whether cilta-cel is effective and safe in adults with relapsed or refractory multiple myeloma who have previously been treated with proteasome inhibitors and immunomodulators.
- Bristol-Myers Squibb K.K. offers Breyanzi, which is a CD19-targeting chimeric antigen receptor T cell therapy, which has been approved in Japan, so it can be used as a second-line treatment for large B-cell lymphoma (LBCL) that has relapsed or refractory, regardless of whether autologous stem cells are involved. JCAR017-BCM-001) also contains cohort 2 of Phase II clinical trials in Europe and Japan, and cohort 3 of Phase III clinical trials in the United States (U.S.) in patients not intended for autologous hematopoietic stem-cell transplantation, The world’s Phase III clinical trials (JCAR017-BCM-003) are for autologous hematopoietic stem cell transplants. The United States Phase II clinical trials (JCAR017-BCM-001) are for people who aren’t going to get autologous hematopoietic stem cells, while Europe and Japan’s cohort 2 Phase II trials are going on.
Key Companies Profiled
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Bayer AG
- Biocon
- AbbVie Inc.
- Johnson & Johnson Private Limited
- Incyte Corporation
- Swedish Orphan Biovitrum
- Genentech
Key Segments Profiled in the Cytokine Release Syndrome Management Industry Survey?
By Cytokine Type:
- Tumor Necrosis Factor-TNF
- Interleukins-II
- Interferons-IFN
- Epidermal Growth Factor-EGF
By Therapeutic Application:
- Cancer
- Asthma
- Airway Inflammation
- Arthritis
- Others
By Biomarker Type:
- Interleukin-10
- Interferon Gamma
- Interleukin-6
- Ferritin
- Cluster of Differentiation-163
By Route of Administration:
- Oral
- Intravenous
By End User:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
